Hanyi Bio-technology (beijing) Co., Ltd.

Deyi Pharmarmaceutical Ltd.

Beijing Inst of Heart Lung & Blood Vessel Diseases

Hanyi Bio-technology Company Ltd.

Xin Tan

Meng Li

Ke Zhang

Zhaohui Yu

Xiangdong Li

Zheng Chen

Yuan Wang

Lei Zhang

Qian Jin

Xue Wang

Junbo Xing

Xuran Zhang

Fengjuan Li

Jie Du

Meng Lian

Tanran Chang

Shubin Wang

Wuxing Sun

Dekai Fan

Youping Ma

A nucleic acid aptamer specifically recognizing soluble ST2 protein and its application, belonging to the field of variation or genetic engineering, are described. The technical problem addressed includes how to specifically detect sST2 protein. In order to address this technical problem, nucleic acid aptamers of single-stranded DNA with nucleotide sequences are shown in SEQ ID No. 1-10, respectively. SELEX technology, combined with high-throughput sequencing technology and bioinformatics analysis, reduces the rounds of screening and obtains candidate nucleic acid aptamers, and further analyzes its affinity and specificity to obtain a nucleic acid aptamer that specifically recognizes sST2 protein. The nucleic acid aptamer has the characteristics of high specificity, high stability, convenient synthesis, and easy labeling of functional groups, and the like, and may be used for the detection of sST2 protein and the preparation of biosensors, diagnosis and prognosis of cardiovascular diseases and other products.

Aptamer for specifically recognizing soluble ST2 protein and application of the same

The present invention belongs to the field of medicine, and relates to use of cannabidiol (CBD) in the treatment of pulmonary arterial hypertension. The CBD can be used as the only active ingredient or combined with other active ingredients to prepare a medicament for treating pulmonary arterial hypertension. Specifically, the present invention relates to use of any one selected from (1) to (3) in the preparation of a medicament for treating and/or preventing pulmonary arterial hypertension: (1) CBD, (2) a plant extract containing the CBD; and preferably, the plant extract is aextract, and (3) a pharmaceutical composition containing the CBD and one or more pharmaceutically acceptable adjuvants. In the present invention, upon experimental researches, it has found that the CBD has the function of inhibiting pulmonary arterial hypertension, and is especially suitable for treating the pulmonary arterial hypertension caused by hypoxemia.

Use of cannabidiol in treatment of pulmonary hypertension

The present invention belongs to the field of medicine, and relates to use of cannabidiol (CBD) in the treatment of pulmonary arterial hypertension. The CBD can be used as the only active ingredient or combined with other active ingredients to prepare a medicament for treating pulmonary arterial hypertension. Specifically, the present invention relates to use of any one selected from (1) to (3) in the preparation of a medicament for treating and/or preventing pulmonary arterial hypertension: (1) CBD, (2) a plant extract containing the CBD; and preferably, the plant extract is a cannabis extract, and (3) a pharmaceutical composition containing the CBD and one or more pharmaceutically acceptable adjuvants. In the present invention, upon experimental researches, it has found that the CBD has the function of inhibiting pulmonary arterial hypertension, and is especially suitable for treating the pulmonary arterial hypertension caused by hypoxemia.

The present invention belongs to the field of biomedicine and relates to use of cannabidiol in the preparation of anti-influenza drugs. Specifically, the present invention relates to use of any one of (1) to (3) below in the preparation of drugs for treating or preventing influenza or drugs for relieving an influenza symptom: (1) cannabidiol or a pharmaceutically acceptable salt or ester thereof; (2) a plant extract containing cannabidiol; preferably, a cannabis extract containing cannabidiol; preferably, an industrial cannabis extract containing cannabidiol; and (3) a pharmaceutical composition, containing an effective amount of cannabidiol or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable auxiliary materials. The cannabidiol can effectively inhibit influenza viruses, and has the potential to prepare or be used as a drug for treating or preventing influenza.

Use of cannabidiol in preparation of drugs for resisting against influenza

The present invention discloses a composition for preventing and/or treating woman dysmenorrhea; the composition includes cannabidiol and/or cannabidivarol, a penetration enhancer as well as a carrier; the mass ratio of the cannabidiol and/or the cannabidivarol to the penetration enhancer is 1:(0.1-0.8). The composition provided by the present invention can effectively relieve woman dysmenorrhea, and solve the problem of lackness of a composition of cannabidiol and/or cannabidivarol which can effectively prevent and/or treat woman dysmenorrhea in the prior art. Meanwhile, the composition provided by the present invention can also be used in preparation of a feminine hygiene product for preventing and/or treating woman dysmenorrhea.

Composition containing cannabidiol and/or cannabidivarol and application thereof in treatment of dysmenorrhea

Growing community of inventors

Beijing, China

Xin Tan